In its April 2026 quarter filing, Fulcrum Therapeutics announced termination of the CAMP4 license agreement covering a Diamond-Blackfan anemia program, signaling a portfolio pruning to refocus resources on pociredir, its lead candidate for sickle cell disease. This decision reflects adaptive management amid early-stage clinical biotech challenges and resource allocation pressures. The company continues to leverage third-party manufacturing and collaborations in developing genetically defined rare disease therapies but faces ongoing capital needs and regulatory uncertainties. Fulcrum’s healthy balance sheet provides runway for near-term clinical milestones, though commercialization remains a future hurdle.